blog

Breast Cancer Is a Workforce Issue: What the Data Tell Us About Equity, Access, and Where Employers Can Help

A breast cancer diagnosis rarely affects only the person receiving it.
It can change a colleague’s schedule, a caregiver’s availability, a family’s finances, and an organization’s ability to retain experienced talent.

That makes breast cancer more than a health issue. It’s also a workforce, caregiving, productivity, and equity issue.

As the Georgia Cancer Control Consortium wrote, “the burden of cancer is not equally shared” (Georgia Cancer Control Consortium, 2024). The data show why employers, HR leaders, benefits teams, and community organizations have a role in improving access, not only to screening, but also to follow-up, diagnosis, treatment, and survivorship support.

Why this belongs on a business agenda

Employees may be managing treatment while trying to remain at work. Others may be caring for a spouse, parent, or child. Some may be grieving a loved one. These experiences can lead to missed work, reduced hours, disrupted career plans, and decisions to leave the workforce.

The barriers identified in breast cancer research are familiar to anyone who has studied employee access to health care:

  • Cost and confusing benefit information
  • Transportation and distance
  • Childcare and eldercare responsibilities
  • Limited appointment availability
  • Language access
  • Delays between an abnormal screening result and diagnostic care
  • Mistrust shaped by historical harms, including the Tuskegee syphilis study and the use of Henrietta Lacks’s cells without consent (Centers for Disease Control and Prevention, n.d.; National Institutes of Health, n.d.)

These barriers don’t operate separately. They often compound one another. A screening appointment may be technically covered, yet still be inaccessible if an employee can’t take unpaid time away from work, arrange childcare, or travel to a facility.

What the data show

Layer A: Georgia and local impact

The American Cancer Society’s Cancer Facts & Figures 2026 projects 10,440 new breast cancer cases and 1,430 breast cancer deaths in Georgia in 2026 (American Cancer Society, 2026). These are projections, not final counts.

Georgia’s racial mortality gap remains substantial. The Georgia Department of Public Health’s Comprehensive Cancer Control Plan 2024–2029 reports that, from 2017 through 2021, non-Hispanic Black women in Georgia were 38% more likely to die of breast cancer than non-Hispanic White women. The age-adjusted mortality rates were 26.8 deaths per 100,000 for non-Hispanic Black women and 19.3 per 100,000 for non-Hispanic White women (Georgia Cancer Control Consortium, 2024).

A separate National Cancer Institute State Cancer Profiles table created in September 2026 reports a breast cancer mortality rate of 26.5 age-adjusted deaths per 100,000 among non-Hispanic Black females in Georgia during 2019–2023, averaging approximately 507 deaths per year (National Cancer Institute, 2026). This is a five-year population measure. It isn’t a real-time 2026 rate or a measure of any individual’s risk.

The broader context is also important. Georgia Department of Public Health data for 2023 show that cancer was the state’s second leading cause of death, accounting for one in five deaths and 18,435 deaths among Georgians (Georgia Department of Public Health, n.d.).

Screening access remains uneven. NCI State Cancer Profiles data for 2024 indicate that 78.8% of Georgia women ages 50–74 reported having a mammogram within the previous two years, compared with 78.5% nationally. Among women ages 40 and older, the figures were 70.9% in Georgia and 72.2% nationally (National Cancer Institute, 2024). These screening and mortality measures cover different periods and shouldn’t be treated as a causal comparison.

Diverse employees discussing flexible scheduling and caregiving support in a workplace

Layer B: The United States

Nationally, the American Cancer Society projects 321,910 new invasive breast cancer cases among U.S. women in 2026, along with 60,730 cases of ductal carcinoma in situ and 42,140 breast cancer deaths among women (American Cancer Society, 2026). The organization reports that breast cancer death rates have declined by approximately 44% since 1989.

Yet progress has not reached all groups equally. Rademacher, Wall, and Huynh (2026) report that the percentage of women ages 40 and older who had a mammogram within the past year was 31% among American Indian and Alaska Native women, 44% among Asian American women, 44% among Hispanic or Latina women, 51% among White women, and 55% among Black women.

The same review reports that rural women were less likely to have ever had a mammogram, with an odds ratio of 0.74, and less likely to be current on screening, with an odds ratio of 0.59. An odds ratio compares the odds of an outcome between two groups; it isn’t the same as a percentage-point difference. Rural patients also had higher odds of a late-stage diagnosis (Rademacher et al., 2026).

The review also cautions that higher screening rates among Black women haven’t consistently produced better outcomes. Longer follow-up times, delays in diagnosis and treatment, and higher mortality demonstrate why screening alone isn’t enough. It references recommendations for race-inclusive breast cancer risk assessment for Black women by age 25 (Rademacher et al., 2026).

Practical barriers matter, too. Appointment nonadherence was 25.1% among women reporting childcare barriers, compared with 15.2% among those without childcare barriers (Rademacher et al., 2026).

Layer C: The global picture

According to WHO and IARC GLOBOCAN 2022, breast cancer accounted for approximately 2.3 million new cases and 670,000 deaths among women worldwide in 2022. It was the most commonly diagnosed cancer among women in 157 of 185 countries (World Health Organization & International Agency for Research on Cancer, 2022).

Approximately 80% of breast cancer cases occur in women without an identifiable risk factor beyond sex and age, and about 0.5%–1% of breast cancers occur in men (World Health Organization, n.d.).

An IARC analysis published in Nature Medicine in 2025 estimated that approximately one in 20 women will be diagnosed with breast cancer during her lifetime and about one in 70 will die from it, with substantial regional variation. If current rates persist, annual global cases could reach approximately 3.2 million, with about 1.1 million deaths per year by 2050 (IARC, 2025).

The WHO Global Breast Cancer Initiative seeks to reduce global breast cancer mortality by 2.5% per year between 2020 and 2040 through early detection, timely diagnosis, and comprehensive treatment (World Health Organization, 2021).

Layer D: Veterans and women veterans

The U.S. Department of Veterans Affairs reported approximately 2.1 million women veterans in 2025. Women veterans are the fastest-growing group within the veteran population and are projected to represent approximately 17%–18% of all veterans by 2040–2043. In 2023, about 930,000 women veterans were enrolled in VA health care, and approximately 650,000 sought VA medical care (U.S. Department of Veterans Affairs, 2025).

VA Health Services Research & Development reports that breast cancer is the most common cancer diagnosed among women veterans within VA. Approximately 87% of eligible women veterans receive mammograms at VA, although barriers include wait times, travel distance, limited women’s health providers, and limited local mammography access (VA Health Services Research & Development, 2025).

VA News reported that approximately 1,200 veterans receiving VA care are diagnosed with breast cancer each year (U.S. Department of Veterans Affairs, 2024).

From 2021 through 2024, the VA Breast and Gynecologic Oncology System of Excellence identified 7,187 incident breast and gynecologic cancers among living veterans. Approximately 78% were breast cancers, and the average age at breast cancer diagnosis was 59. Women veterans were diagnosed at younger ages than the general U.S. population (VA Health Services Research & Development, 2025).

Georgia is home to approximately 650,739 veterans, including nearly 93,000 women veterans (Georgia Department of Veterans Service, 2025). These figures may vary by source and reporting year.

Screening isn’t the finish line

Breast cancer equity depends on the full continuum of care:

  1. Risk assessment and prevention education
  2. Screening
  3. Follow-up after an abnormal result
  4. Diagnostic imaging and biopsy
  5. Timely treatment
  6. Survivorship and return-to-work support

A New York City mobile mammography program served 32,350 women, provided additional testing for more than 5,000 abnormal results, and diagnosed 68 breast cancers (Rademacher et al., 2026). Those figures must be interpreted with an important caveat: recall rates are higher on mobile units, and patients with recalls return for additional imaging less often.

The lesson is clear. Organizations should measure follow-up completion, not just screening volume.

Woman veteran speaking with a healthcare navigator about follow-up care

What works

The intervention evidence points toward practical, layered support.

Rademacher et al. (2026) report that vouchers increased screening from 17.5% to 87% in one randomized trial among Hispanic migrant women. Eliminating cost sharing increased screening, particularly among younger women. A DVD-based intervention had an odds ratio of 1.84, while a DVD intervention combined with navigation had an odds ratio of 5.69.

Navigation showed the greatest benefit in low-resource systems and may take three months or longer to show measurable impact (Rademacher et al., 2026). That timeline matters for governance. Short evaluation windows may understate program value.

What organizations can do

Employers and community organizations can take realistic steps:

  • Review benefit communications. Explain coverage, deductibles, copayments, eligibility, and follow-up services in plain language.
  • Provide paid time off and flexible scheduling. This should include screening, diagnostic appointments, treatment, follow-up, and survivorship care.
  • Support caregivers. Consider flexible hours, predictable scheduling, leave options, remote work where appropriate, and confidential guidance about available benefits.
  • Build language access into care navigation. Ensure interpretation and translated materials are available.
  • Consider navigation support. Navigation can help employees address scheduling, transportation, childcare, referrals, and administrative barriers.
  • Protect privacy and dignity. Employees shouldn’t have to disclose more medical information than necessary to receive support.
  • Measure the whole pathway. Track time from screening to follow-up, diagnostic completion, treatment initiation, and return-to-work support, not only the number of screenings completed.
  • Evaluate with realistic timelines. Navigation and other access interventions may need three months or longer before their effect becomes visible.

Limitations and takeaway

These data come from different years, populations, methods, and definitions. Georgia projections aren’t the same as confirmed cases. Age-adjusted rates allow populations with different age structures to be compared; they don’t describe individual risk. Screening data are often self-reported. Global projections assume current rates persist. Veteran figures may reflect VA users rather than all veterans.

Even with those limitations, the direction is consistent: access is not simply whether a benefit exists. It’s whether people can use it in time.

Breast cancer affects employees, caregivers, families, and organizations. Employers can’t solve every structural barrier, but they can reduce the friction that turns a manageable appointment into a missed appointment, or a delay in diagnosis into a larger disruption.

Perhaps the most useful next step is an internal review: Where does our organization make breast cancer care easier, and where might our policies unintentionally make it harder?

That question can lead to clearer benefits communication, more humane scheduling, stronger caregiver support, and better measurement across the full continuum of care.

Medical disclaimer

This article is for educational and professional discussion purposes only. It isn’t medical, legal, employment, or benefits advice. Screening and treatment decisions should be made with a qualified health professional. Employers should consult appropriate legal and benefits professionals when reviewing workplace policies.

References

American Cancer Society. (2026). Cancer facts & figures 2026. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2026-cancer-facts-figures.html

American Cancer Society. (2026). Estimated number of new cases for selected cancers by state, 2026. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/mr4-cases-by-state-2026-branded.pdf

Centers for Disease Control and Prevention. (n.d.). About the Tuskegee study. https://www.cdc.gov/tuskegee/

Georgia Cancer Control Consortium. (2024). Georgia comprehensive cancer control plan 2024–2029. https://www.georgiacancer.org/wp-content/uploads/2025/04/2024-2029-Comprehensive-Cancer-Control-Plan.pdf

Georgia Department of Public Health. (n.d.). Comprehensive Cancer Control Program. https://dph.georgia.gov/chronic-disease-prevention/comprehensive-cancer-control-program

Georgia Department of Veterans Service. (2025). Veteran population estimates. https://veterans.georgia.gov/

International Agency for Research on Cancer. (2025). Breast cancer cases and deaths are projected to rise globally. https://www.iarc.who.int/news-events/breast-cancer-cases-and-deaths-are-projected-to-rise-globally/

National Cancer Institute State Cancer Profiles. (2026). Death rates: Breast cancer, Georgia [Data table]. https://statecancerprofiles.cancer.gov/

National Cancer Institute State Cancer Profiles. (2026). Quick profiles: Georgia. https://statecancerprofiles.cancer.gov/quick-profiles/index.php?statename=georgia

National Institutes of Health. (n.d.). Henrietta Lacks and the HeLa cell genome. https://www.nih.gov/

Rademacher, N., Wall, C. S., & Huynh, V. D. (2026). Barriers to solutions: A framework guided review of social determinants of breast cancer screening and interventions designed to address them. Current Breast Cancer Reports, 18, 50. https://doi.org/10.1007/s12609-026-00672-y

U.S. Department of Veterans Affairs. (2024). Breast cancer screenings could save your life. VA News. https://news.va.gov/

U.S. Department of Veterans Affairs. (2025). Facts and statistics: Women veterans health care. https://www.womenshealth.va.gov/materials-and-resources/facts-and-statistics.asp

U.S. Department of Veterans Affairs, Health Services Research & Development. (2025). Women veterans' cancer care research. https://www.hsrd.research.va.gov/centers/womens_health/cancer-care-snapshot.pdf

World Health Organization. (n.d.). Breast cancer [Fact sheet]. https://www.who.int/news-room/fact-sheets/detail/breast-cancer

World Health Organization. (2021). Global breast cancer initiative. https://www.who.int/initiatives/global-breast-cancer-initiative

World Health Organization & International Agency for Research on Cancer. (2022). GLOBOCAN 2022: Breast cancer fact sheet. https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *